Turmeric and Chinese goldthread synergistically inhibit prostate cancer cell  proliferation and NF-kB signaling by Yi Zhao et al.
Functional Foods in Health and Disease 2014; 4(7):312-339  Page 312 of 339 
 
Research Article                         Open Access 
 
Turmeric and Chinese goldthread synergistically inhibit prostate cancer cell 
proliferation and NF-kB signaling 
 
                    Yi Zhao
1, J. Jason Collier
1*, E-Chu Huang
1 and Jay Whelan
1,2 
 
1Department of Nutrition, 229 Jessie Harris Building, and 
2Tennessee Agricultural Experiment 
Station, University of Tennessee, Knoxville, TN 37996, USA 
 
Corresponding Author: Jay Whelan, Department of Nutrition, Laboratory for Cancer Research, 
1215 West Cumberland Avenue, Room 229 Jessie Harris Building, University of Tennessee, 
Knoxville, TN 37996-1920, USA 
 
Submission date: June 10, 2014; Acceptance date: July 16, 2014; Publication date: July 21,  
2014 
 
 
ABSTRACT: 
Background: Pre-clinical studies using bioactive compounds from botanicals appear to offer 
some  protection  against  cancer.  Research  using  single  bioactives  contributes  greatly  to  our 
understanding of their mechanism of action, but in vitro studies demand concentrations that are 
higher than achievable in humans (µM). However, maintaining these bioactives in the presence 
of other compounds originally derived from the food or extract of origin may synergistically 
lower the bioactive dose so translatability becomes feasible. The objective of this study was to 
determine if bio-efficacy of phytonutrients can be enhanced when used in combination even at 
doses that are ineffective for any compound when used in isolation.  
 
Methods:  The  anti-proliferative  and  molecular  effects  of  herbs  (turmeric  and  Chinese 
goldthread)  and  their  bioactives  (curcumin  and ar-turmerone,  berberine  and  coptisine, 
respectively) were determined in isolation and in combination. Using CWR22Rv1 and HEK293 
cells, cell proliferation (as assessed by the MTT assay) and NF-κB promoter activity (using a 
luciferase reporter construct) were evaluated and synergy of action was assessed by the Chou-
Talalay method utilizing CompuSyn
® software.  
 
Results:  Turmeric  and  Chinese  goldthread  act  synergistically  (combination  index<1)  when 
inhibiting cell proliferation with all cell lines tested. The synergy of action of combinations of 
companion bioactives from the same herb (i.e., curcumin/ar-turmerone and berberine/coptisine) 
and bioactives from different herbs (i.e., curcumin/berberine) help to explain why turmeric and 
Chinese goldthread are more effective than their major bioactives in isolation. At the molecule 
level,  curcumin+ar-turmerone  and  curcumin+coptisine  synergistically  attenuated  TNFα-
stimulated  NF-κB  promoter  activity.  Even  compounds  with  poor  efficacy  become  more 
biologically  active  in  the  presence  of  companion  compounds.  Importantly,  the  effects  of Functional Foods in Health and Disease 2014; 4(7):312-339  Page 313 of 339 
combining  any  two  bioactives  or  herbal  extracts  were  highly  synergistic  at  concentrations 
approaching physiological significance (nanomolar). 
 
Conclusions: These results suggest that bioactives in combination (as plant extracts or isolated 
compounds) are highly synergistic at the cellular and molecular level at physiologically relevant 
concentrations. These data help to explain why complex mixtures of botanicals may be more 
efficacious than their bioactives in isolation. 
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BACKGROUND: 
Research exploring the use of natural products, such as botanicals, herbs, herbal extracts, and 
their isolated bioactives are becoming increasingly appealing because of their potential efficacy 
in attenuating growth and viability of cancer cells with few observed side effects in humans 
when these agents are taken orally. The combination of multiple botanicals may prove to be 
more efficacious as compared with their use in isolation. These effects may be related to the fact 
that  when  bioactives  are  used  in  combination,  their  synergy  could  reduce  the  concentration 
needed for effectiveness to one that is physiologic. For example, polyherbal mixtures can be 
quite effective in inhibiting cancer cell proliferation when individual herbal extracts have no 
effect (see Supplemental Figure 1). Furthermore, in vitro studies demand concentrations (often in 
the 20-100 µM range) [1, 2] that are several orders of magnitude higher than nM concentrations 
achievable  in  humans.  The  difference  between  these  effects  seen  in  vitro  using  micromolar 
concentrations when compared with the nanomolar concentrations measured in humans raises 
the issue of the translational relevance of some of the in vitro studies, which likely accounts for 
at least part of the disappointing outcomes in clinical trials [3]. Tables 1 and 2 summarize this 
point where the mean IC50 concentrations observed in a variety of cancer cell lines are 41 µM, 21 
µM, >243 µM and 29 µM for the bioactives berberine, curcumin, ar-turmerone and coptisine, 
respectively, while the serum/plasma concentrations in humans provided oral doses of curcumin 
are in the nanomolar range. With one exception, the serum/plasma levels of curcumin are <200 
nM at doses as high as 12 g (Table 2). Maintaining an individual bioactive in the presence of 
other  bioactive  compounds  (originally  derived  from  the  food  or  extract  of  origin)  may  turn 
isolated compounds that have weak bioactivity to those that have substantially more activity at 
lower doses. This would make translation to humans more feasible. For instance, the World 
Cancer  Research  Fund/American  Institute  for  Cancer  Research  reports  that  consumption  of 
individual nutrients could in some instances result in vastly different outcomes when compared 
with their foods of origin [4]. This concept of the importance of the complex source versus 
isolated nutrients is echoed by the American Cancer Society [5]. Importantly, this concept can be 
equally applied to combinations of foods or botanicals. 
To investigate the synergistic action of botanicals, we used CWR22Rv1 and HEK293 cells. 
CWR22Rv1  cells  are  an  in  vitro  model  of  castrate-resistant  prostate  cancer  (PCa)  [6]  and 
complement our research investigating the effects of a mixture of bioactive botanicals on in vitro Functional Foods in Health and Disease 2014; 4(7):312-339  Page 314 of 339 
and in vivo models of castrate-resistant PCa [7-9]. The HEK293 cell line is a transformed human 
embryonic kidney cell that is widely used as a tool for expression vectors [10]. In this case, 
HEK293 cells were transfected with a recombinant plasmid expressing a luciferase gene under 
the control of a multimerized NF-κB responsive-promoter stimulated with TNFα [11]. 
In  Traditional  Chinese  Medicine  [12],  Chinese  goldthread  and  turmeric  are  used  in 
combination to treat a variety of diseases, among them cancer. Cancer has been explained as a 
combination  of  damp-heat  and  blood  stasis  [2,  3]  where  the  anti-cancer  effects  of  Chinese 
goldthread  and  turmeric  can  be  explained  as  damp-heat  removing  [2,  13]  and  blood  stasis 
improving  [13],  respectively.  The  use  of  Chinese  goldthread  and  turmeric  complement  our 
previous studies involving a polyherbal mixture containing these two herbal extracts [7-9]. 
While Chinese goldthread (Coptis chinensis) has been tested in a number of cancers [14-17], 
very  little  is  known  about  its  impact  on  PCa.  Instead,  berberine,  the  major  bioactive 
phytochemical in Chinese goldthread (estimated to be ~6% [18, 19]) has been preferentially Functional Foods in Health and Disease 2014; 4(7):312-339  Page 315 of 339 
studied and has been found to inhibit cell growth at concentrations of 30 µM to 100 µM in 
androgen-dependent and androgen-independent PCa cells [17, 20, 21].  
 
Table 2. Effect of oral dosing of curcumin from a single dose (g) to 24 weeks treatment (g/d) on 
maximum serum/plasma concentrations (nM) of curcumin and its metabolic derivatives 
 
Reference    Dose    Curcumin       Total Curcumoids  
               (underivatized)    (curcumin + derivatives) 
        (g)    (nM)          (nM)   
                                    
LC or GC Mass Spectral Analysis  
[54]        0.45    nd 
          1.8    nd 
          3.6    nd-11          35.8 
[55]        4    21          149 
[56]      0.03    4.9 
 
HPLC-UV Detection 
[57]      2    nd 
        4    nd 
        6    nd 
        8    nd 
        10    137 
        12    157 
[58]        4    510 
        6    630 
        8    1770 
[59]      0.45    <3              <3 
        1.8    <3          <3 
        3.6    <3          <3 
[60]      0.036    nd          nd 
        0.072    nd          nd 
        0.108    nd          nd 
        0.144    nd          nd 
        0.18    nd          nd 
[61]      2    nd 
[62]      12    nd 
                                    
nd: not detectable. 
 
A minor constituent in this herb is coptisine (ratio of berberine to coptisine is approximately 
5:1) [18]; however, this compound and the potential synergy between these compounds has yet 
to be tested. Turmeric (Curcuma longa) is a plant commonly found in Asia from the ginger Functional Foods in Health and Disease 2014; 4(7):312-339  Page 316 of 339 
family. Like Chinese goldthread, extracts of turmeric are not typically used in studies; instead 
curcumin, one of its primary ingredients known for its anticancer properties, is the primary target 
of investigation [22, 23]. Curcumin is the major curcuminoid in turmeric at a level of ~5-6% [24, 
25].  The molecular targets  of curcumin are extensive (as reviewed  elsewhere  [22, 26]). For 
example, curcumin has been shown to modify those targets involved in inflammation, apoptosis, 
angiogenesis, metastasis and the expression of transcription factors, various receptors, growth 
factors and a variety of protein kinases. However, curcumin inhibits androgen-dependent and 
androgen-independent PCa cell growth at concentrations of 40 µM to 100 µM [27]. While the 
diversity of compounds in turmeric is extensive [28, 29], a less commonly studied one is ar-
turmerone  from  the  sesquiterpenes  (ratio  of  curcumin  to  ar-turmerone  in  turmeric  is 
approximately 4:1) [30, 31], with reported IC50 values in a variety of cancer cell lines of  >243 
µM [32-36]; however, ar-turmerone has not been studied in PCa. Similarly, the potential synergy 
between these compounds has yet to be tested. The objective of this study was to build upon the 
concept that the combination of bioactives in botanicals is far more effective than an individual 
bioactive  in  isolation.  While  this  seems  intuitive,  a  systematic  approach  yielding  solid 
experimental evidence has  yet  to  be fully  explored. To address  this  issue, we determined if 
synergy  could  explain  the  enhanced  effect  of  (a)  the  combination  of  herbs  over  isolated 
bioactives derived from those herbs, (b) the combination of bioactives over isolated bioactives 
derived  from  the  same  herb  (companion  compounds),  (c)  the  combination  of  herbs  over 
individual  herbs,  (d)  the  combination  of  bioactives  from  different  herbs  over  the  isolated 
bioactives, and (e) whether these synergistic effects on proliferation can apply at the molecular 
level. NF-κB transcriptional activity was chosen as the molecular target because of its link in 
castrate-resistant  PCa  [37,  38]  and  because  it  has  been  previously  identified  as  a  target  of 
bioactive phytonutrients and natural products [39, 40]. 
 
MATERIALS AND METHODS:  
Experimental design: The experimental design for testing synergistic interactions is presented 
in Figure 1. The comparisons made in this study included the combinations of herbs (inter-
interactions),  comparison  of  the  herb  to  its  major  bioactive  (i.e.,  Chinese  goldthread  versus 
berberine and turmeric versus curcumin), combinations of bioactives from the same herb (intra-
interaction) and combinations of bioactives from different herbs (inter-interactions).  
 
Chemicals: The herbal extracts of Chinese goldthread (Coptis chinensis) and turmeric (Curcuma 
longa)  were  provided  by  New  Chapter  (Brattleboro,  VT).  Fourier  transform  infrared 
spectroscopy was used to independently identify the raw materials and they were further verified 
by independent laboratories using a variety of analytical approaches (i.e., high performance and 
thin  layer  chromatographies  and  mass  spectrometry)  (as  described  previously)  [63].  Quality 
control was determined by ranges of select bioactives, such as curcuminoids in turmeric and 
berberine  in  Chinese  goldthread  [63].  Berberine  (98%  purity)  was  purchased  from  MP 
Biomedicals  (Solon,  OH),  curcumin  (98%  purity)  from  Fischer  Scientific  (Pittsburgh,  PA), 
coptisine  (98%  purity)  from  Quality  Phytochemicals  (Edison,  NJ),  and  ar-turmerone  (90% 
purity)  from  Sigma-Aldrich  (St.  Louis,  MO).  All  substances  were  dissolved  in  dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO) to varied stock concentrations. RPMI 1640 Functional Foods in Health and Disease 2014; 4(7):312-339  Page 317 of 339 
cell culture media (Invitrogen, Grand Island, NY), supplemented with 0.5% fetal bovine serum 
(FBS, Invitrogen, Grand Island, NY) was used to dilute each stock solution to the required final 
concentrations.  
 
 
Figure  1.  Experimental  design.  Comparisons  were  made  between  herbs  and  their  major 
bioactives,  among  combinations  of  herbs  (inter-interaction  of  herbs)  and  combinations  of 
bioactives from the same herb (intra-interaction of isolated bioactives) or different herbs (inter-
interactions of isolated bioactives). 
 
Cell  Culture:  For  the  experimental  treatments,  CWR22Rv1  cells  (American  Type  Culture 
Collection, Rockville, MD), a human-derived castrate-resistant PCa line, were grown in RPMI 
1640 media supplemented with 10% FBS under an atmosphere of 5% CO2 at 37°C. Prior to the 
experiments, the level of FBS was reduced to 0.5%. HEK293 cells (ATCC, Rockville, MD), a 
human embryonic kidney cell line, were grown in DMEM media supplemented with 10% FBS 
under an atmosphere of 5% CO2 at 37°C. 
 
Cell  Proliferation:  Cell  growth  and  proliferation  inhibition  studies  were  performed  using 
standard  96  well  plates  and  analyzed  with  the  MTT  [3-(4,  5-dimethylthiazol-2-yl)-2,  5-
diphenyltetrazolium  bromide]  (Chalbiochem,  Darmstadt,  Germany)  assay  following  the 
manufacturer’s instructions. CW22Rv1 cells were plated at a density of 2×10
4 cells per well. 
After 24 hours, the FBS concentration in the cell culture media was reduced to 0.5% FBS and the 
cells were incubated overnight prior to the addition of the herbal extracts or phytochemicals. Functional Foods in Health and Disease 2014; 4(7):312-339  Page 318 of 339 
HEK293 cells were plated at a density of 1×10
4 cells per well. After 24 hours, the cells were 
incubated  with  herbal  extracts  or  phytochemicals.  After  48  hr  incubation,  cell  viability  and 
proliferation were measured via the MTT assay. Briefly, medium was replaced by 100 µl of 0.5 
mg/ml MTT and cells were incubated for 4 hr at 37°C. Intracellular formazan crystals were 
solubilized  with  100  µl  isopropanol/0.04  N  HCl.  Absorbance  was  read  at  540  nm  on  a 
SpectraCount microplate photometer (Perkin Elmer Inc, Waltham, MA). 
 
Transfection and luciferase assay: The multimerized NF-κB promoter luciferase vector has 
been  described  elsewhere  [11].  Transient  transfection  of  luciferase  reporter  constructs  into 
HEK293 cells was achieved using Lipofectamine
® 2000 (Life technologies, Grand Island, NY) 
following manufacturer’s instructions. Briefly, HEK293 cells were plated at a density of 1.5×10
4 
cells per well in 96 well plates. After 24 hours, 4 ng/well plasmid was transfected with 0.32 
μl/well Lipofectamine
® 2000. After incubating overnight, transfection medium was removed and 
cells were incubated with herbal extracts or phytochemicals in 0.5% FBS supplemented DMEM 
medium for 1 hr. After incubation, HEK293 cells with luciferase reporter were stimulated by 5 
ng/ml TNF-α for 4 hr.  Whole cell lysate was achieved by 20 μl passive lysis buffer (Promega, 
Madison, WI) and 10 μl was used for luciferase activity measurement by using the Luciferase 
Assay Reagent (Promega, Madison, WI). Luciferase activity was detected using the GloMax 
plate reading luminometer and normalized to total cellular protein concentration per well using 
the BCA assay (Thermo Scientific, Rockford, IL) following manufacturer’s instruction. 
 
Assessment  of  Synergistic,  Additive  or  Antagonistic  Effects  of  Combinations  of  Herbal 
Extracts  and/or  Phytochemicals:  To  calculate  the  effects  of  compounds  or  herbs  in 
combination, IC50 values were determined for each ingredient. For the experiments with the 
combination  of  herbal  extracts,  turmeric  and  Chinese  goldthread  were  combined  at  a 
concentration  equivalent  to  their  IC50  values  followed  by  serial  dilutions  to  generate  a  dose 
response. For the experiments that combined individual bioactive phytochemicals from different 
herbal extracts (berberine and curcumin), they were combined at concentrations equivalent to 
their IC50 values, followed by serial dilutions to generate a dose response. For the experiments 
that combined individual bioactive phytochemicals from the same herbal extract (i.e., berberine 
and coptisine, curcumin and ar-turmerone), they were combined at concentrations equivalent to 
their IC50 values or based on their relative ratios in their respective herbal extracts followed by 
serial dilutions to generate dose responses.  
Assessment of synergistic, additive or antagonistic effects of combinations was determined 
using the Chou-Talalay method [64]. This method is derived from mass-action law principles as 
described in detail elsewhere [65]. The combination index (CI) and dose-reduction index (DRI) 
were  used  to  differentiate  synergy,  antagonism  and  additive  effects  for  combinations  of 
components. CI and DRI were generated for all treatments with CompuSyn
® 1.0 (Combo Syn, 
Paramus, NJ) according to the manufacturer’s instructions. CompuSyn
® 1.0 software uses an 
algorithm  based  on  the  Chou-Talalay  method  to  simulate  the  interaction  of  2  or  more 
compounds. Briefly, concentrations and corresponding effect levels for all data points were input 
to generate a complete report of analytical results. CI is a parameter that indicates whether the 
interaction  of  two  compounds  is  synergistic,  additive,  or  antagonistic  [additive  (CI  =  1); Functional Foods in Health and Disease 2014; 4(7):312-339  Page 319 of 339 
synergistic (CI < 1); antagonistic (CI > 1)]. DRI is a parameter that indicates the degree to which 
the  concentration  of  a  compound  can  be  reduced  when  used  in  combination  with  another 
compound  to  maintain  an  equivalent  effect.  The  use  of  CI  and  DRI  provide  numerical 
assessments of not only whether there is synergy, but the extent of that synergy and synergy at 
particular doses [64]. 
 
Statistical Analysis: The results were presented as mean ± SEM and were analyzed by two-
tailed student’s T-test. Differences were considered significant at p<0.05.  
 
RESULTS: 
Cell proliferation:  
Dose response curves were generated for all bioactives tested in each cell type. All the bioactives 
and their extracts of origin reduced cell proliferation in a dose dependent manner (Fig. 2). IC50 
values of bioactives were used, in part, to determine the synergistic effect between different 
bioactives. 
 
Figure 2. The effects of berberine, coptisine, curcumin, ar-turmerone, Chinese goldthread and 
turmeric on cell proliferation. Dose-response curves for cell proliferation were generated with 
berberine,  coptisine,  curcumin,  ar-turmerone  using  (A)  CWR22Rv1  cells  and  (B)  HEK293 
cells.  (C)  Dose-response  curves  for  cell  proliferation  were  also  generated  with  the  herbal 
extracts of Chinese goldthread and turmeric for both cell lines. IC50 values of bioactives and 
herb extracts were generated from these curves. 
 
Comparisons of Chinese goldthread with berberine, and turmeric with curcumin on cell 
proliferation: Dose-response curves were generated for Chinese goldthread, berberine, turmeric 
and curcumin and their effectiveness inhibiting cell proliferation were compared based on the 
relative amounts of the phytonutrients in the herbal extract (i.e., the amount of  berberine in 
Chinese goldthread and the amount of curcumin in turmeric). Proliferation of CWR22Rv1cells 
and  HEK293  cells  was  reduced  in  dose-dependent  manners  with  Chinese  goldthread  and 
berberine (Fig. 2). Following normalization based on the relative amount of berberine in Chinese 
goldthread, there was a shift to the left in the IC50 value, from 30 µM to 19 µM in CWR22Rv1 
cells (Fig. 3A) and from 30 µM to 11 µM in HEK293 cells (Fig. 3C).  
Cell proliferation was also reduced in dose-dependent manners with turmeric and curcumin 
(Fig. 2). Following normalization based on the relative amount of curcumin in turmeric, there 
was a shift to the left of the IC50 value from 22 µM to 9.5 µM in CWR22Rv1 cells (Fig. 3B) and 
from 11 µM to 4 µM in HEK293 cells (Fig. 3D). These results collectively infer that other Functional Foods in Health and Disease 2014; 4(7):312-339  Page 320 of 339 
compounds within the original herbal extracts (companion compounds) may be acting in concert 
(i.e.,  synergism)  with  each  of  the  bioactive  phytonutrients.  To  explore  this  possibility,  we 
investigated the effects of combining companion phytonutrients from Chinese goldthread (i.e., 
berberine with coptisine) and turmeric (i.e., curcumin with ar-turmerone). 
 
Intra-herbal  comparisons  of  companion  phytonutrients  (berberine  with  coptisine, 
curcumin with ar-turmerone) on cell proliferation: Berberine and coptisine are two bioactive 
phytonutrients found in Chinese goldthread (companion phytonutrients) and their synergy could 
help explain, in part, the enhanced effectiveness of Chinese goldthread when compared with 
berberine in isolation. Berberine and coptisine reduced the proliferation of CW22Rv1 cells in 
dose-dependent  manners with  IC50 values of 30 µM  and 85 µM,  respectively  (Fig. 2).  In a 
similar manner, the proliferation of HEK293 cells was reduced by berberine and coptisine with 
IC50 values of 30 µM and 70 µM, respectively (Fig. 2). To determine the effects on proliferation 
with  the  combination,  cells  were  treated  with  berberine  plus  coptisine  with  serial  dilutions 
starting with concentrations equivalent to their IC50 values (30 µM:85 µM for CWR22Rv1, 30 
 
 
 
Figure 3. The comparison of berberine and curcumin on cell proliferation compared to their 
herbal extracts of origin, Chinese goldthread and turmeric, respectively, in CWR22Rv1 cells 
and  HEK293  cells.  Following  normalization  based  on  the  relative  amount  of  berberine  in 
Chinese goldthread and the relative amount of curcumin in turmeric, dose-response curves were 
compared between Chinese goldthread and berberine in (A) CWR22Rv1 cells and (C) HEK293 
cells,  and between turmeric and curcumin in  (B) CWR22Rv1 cells  and (D) HEK293 cells. 
Compared to individual compounds, herbal extracts had a more pronounced effect on reducing 
cell proliferation compared to their isolated bioactives (shifts in IC50 values to the left). 
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µM:70 µM for HEK293) and reducing these to nanomolar concentrations while maintaining the 
same ratio. The combination of berberine plus coptisine reduced cell proliferation in a dose-
dependent  manner  and  the  minimum  effective  doses  were  determined  for  both  single 
phytochemicals and their combinations (Tables 3 and 4). CI and DRI values were generated for 
minimum effective doses by CompuSyn® 1.0, respectively. The combination of berberine plus 
coptisine reduced the minimum effective doses from µM level to nM level in CWR22Rv1 cells 
(7.5 µM for berberine, 21 µM for coptisine, and 0.24 µM+0.66 µM for their combination) and 
was highly synergistic in inhibiting cell growth at this level (CI equal to 0.05), with the DRIs 
being 52 and 37 when combined at the lowest concentrations (0.24 µM+0.66 µM). This means 
the addition of berberine to coptisine or coptisine to berberine reduced the effective doses 52 and 
37  fold,  respectively,  compared  with  each  alone.  In  a  similar  manner,  the  combination  of 
berberine plus coptisine also reduced the minimum effective doses significantly in HEK293 cells 
(15 µM for berberine, 17.5 µM for coptisine, and 3.75 µM+8.75 µM for combination) and was 
highly synergistic in inhibiting cell growth at this level (CI equal to 0.42 with the DRIs being 3.2 
and 32). 
Curcumin and ar-turmerone (two bioactive phytonutrients found in turmeric) reduced the 
proliferation of CW22Rv1 cells in dose-dependent manners with IC50 values of 22 µM and 150 
µM, respectively (Table 3). In a similar manner, the proliferation of HEK293 cells was reduced 
by curcumin and ar-turmerone with IC50 values of 11 µM and 200 µM, respectively (Table 4). 
To determine the effects on proliferation with the combination, cells were treated with curcumin 
plus  ar-turmerone  with  serial  dilutions  starting  with  concentrations  equivalent  to  their  IC50 
values (22 µM:150 µM for CWR22Rv1, 11 µM:200 µM for HEK293) and reducing these to 
nanomolar concentrations while maintaining the same ratio (Tables 3 and 4). The dose-response 
curves with the combination of curcumin plus ar-turmerone reduced cell proliferation in a dose-
dependent  manner.  The  combination  of  curcumin  plus  ar-turmerone  reduced  the  minimum 
effective doses in CWR22Rv1 cells (5.5 µM for curcumin, 9.4 µM for ar-turmerone, and 0.17 
µM +1.2 µM for their combination) and was highly synergistic in inhibiting cell growth at this 
level (CI equal to 0.09 with the DRIs being 37 and 16). In a similar manner, the combination of 
curcumin plus ar-turmerone also reduced the minimum effective doses significantly in HEK293 
cells (11 µM for curcumin, 200 µM for ar-turmerone, 0.69 µM+25 µM for their combination) 
and was highly synergistic in inhibiting cell growth at this level (CI equal to 0.45 with the DRIs 
being 14 and 2.6). 
While it is standard practice to use the ratio of the IC50 values to evaluate synergy, the ratio 
of these bioactive phytonutrients from their respective herbal extracts are different. For example, 
the ratio of berberine to coptisine in Chinese goldthread is ~5:1, and curcumin to ar-turmerone is 
~4:1.  As  such,  synergy  was  also  assessed  at  more  “natural”  ratios  (Tables  3  and  4).  For 
CWR22Rv1  cells,  the  combination  of  berberine  and  coptisine  was  highly  synergistic  in 
inhibiting cell growth at minimum effective concentrations (0.469 µM+0.094 µM) where the CI 
was 0.16, respectively. The DRI values at these concentrations were 6.8 and 14.6 for berberine 
and coptisine, respectively. Similarly, using HEK293 cells, the combination of berberine and 
coptisine in a 5:1 ratio was highly synergistic in inhibiting cell growth in minimum effective 
concentrations (1.88 µM+0.38 µM) where the CI was 0.10, respectively. The DRI values at these 
concentrations were 11 and 109 for berberine and coptisine, respectively. Functional Foods in Health and Disease 2014; 4(7):312-339  Page 322 of 339 
Using CWR22Rv1 cells, the combination of curcumin plus ar-turmerone were also highly 
synergistic  in  inhibiting  cell  growth  at  concentrations  as  low  as  0.344  µM+0.086  µM, 
respectively (Table 3), where the CI was 0.06. The DRI values at these concentrations were 17.6 
and 187 for curcumin and ar-turmerone, respectively. Using HEK293 cells, the combination of 
curcumin  and  ar-turmerone  was  synergistic  in  inhibiting  cell  growth  at  minimum  effective 
concentrations of 11 µM+2.75 µM, respectively, where the CI was 0.64 (Table 4). The DRI 
values at these concentrations were 2.4 and 3.8 for curcumin and ar-turmerone, respectively. 
 
Inter-herbal  comparison  of  the  extracts  of  Chinese  goldthread  with  turmeric  on  cell 
proliferation:  The  extracts  of  Chinese  goldthread  and  turmeric  reduced  the  proliferation  of 
CWR22Rv1 and HEK293 cells in dose-dependent manners (IC50 values for CWR22Rv1 cells 
were 130 µg/ml and 65 µg/ml, for HEK293 cells were 80 µg/ml and 30 µg/ml, respectively) 
(Fig. 2). To determine the effects on proliferation with the combination, cells were treated with 
Chinese goldthread plus turmeric  with  serial  dilutions  starting with  combined concentrations 
equivalent to their IC50 values (130 µg/ml:65 µg/ml for CWR22Rv1 cells and 80 µg/ml:30 µg/ml 
for HEK293 cells) and going as low as ≤1 µg/ml (maintaining the same ratio). The combination 
of Chinese goldthread plus turmeric qualitatively reduced cell proliferation in a dose-dependent 
manner for both cell lines (Tables 3 and 4). CI and DRI values were generated at minimum 
effective concentrations. For CWR22Rv1 cells, the minimum effective concentration was more 
than 100 times lower than their respective IC50 values (1.103 µg/ml+0.508 µg/ml, respectively). 
The combination of Chinese goldthread and turmeric were highly synergistic in inhibiting cell 
growth at these doses, where the CI was 0.04, respectively. The DRI values at the minimum 
effective concentrations were 51.6 and 52.1 for Chinese goldthread and turmeric, respectively. 
Using HEK293 cells, the minimum effective concentrations were significantly reduced to 10 
µg/ml+3.75 µg/ml. The combination was highly synergistic at these doses, where the CI was 
0.29. The DRI values at the minimum effective concentrations were 6.8 and 6.8, respectively. 
 
Inter-herbal comparison of phytonutrients (berberine with curcumin): To explain, in part, 
the synergism between Chinese goldthread and turmeric, isolated bioactive compounds from 
each herb (i.e., berberine and curcumin) were evaluated for synergy. To determine the effects on 
proliferation with the combination, cells were treated with berberine plus curcumin with serial 
dilutions  starting  with  concentrations  equivalent  to  their  IC50  values  (30  µM:22  µM  for 
CWR22Rv1  cells  and  30  µM:11  µM  for  HEK293  cells)  and  reducing  these  to  nanomolar 
concentrations while maintaining the same ratio. The combination of berberine plus curcumin 
reduced cell proliferation in a dose-dependent manner for both cell lines (Tables 3 and 4). CI and 
DRI values were generated for minimum effective concentrations. For CWR22Rv1 cells, the 
combination of berberine and curcumin was highly synergistic in inhibiting cell growth at these 
levels (CI equal to 0.08, respectively), with the DRIs being 23.5 and 23.7 when combined at the 
minimum  effective  concentrations  (0.235  µM+0.172  µM)  (Table  3).  Similar  results  were 
observed with HEK293 cells (Table 4). The combination of berberine and curcumin was highly 
synergistic in inhibiting cell growth at these levels (CI equal to 0.32), with the DRIs being 5.3 
and 7.5 when combined at the minimum effective concentrations (3.75 µM+1.38 µM). 
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Table  3:  Dose-effect  relationships  of  berberine  and  coptisine  (from  Chinese  goldthread), 
curcumin  and  ar-turmerone  (from  turmeric),  Chinese  goldthread  and  turmeric  and  their 
combinations using their IC50 values or using ratios corresponding to relative amounts in their 
native extracts on proliferation of CWR22Rv1 cells. 
Isolated compounds 
and combinations 
Minimum 
Effective Dose 
(µM)
a 
IC50 
(µM) 
Combination 
Index (CI) 
Dose Reduction Index 
(DRI) 
Berberine  7.5  30     
Coptisine  21  85     
Ber + Cop 
(ratio = 1 : 2.8)
b 
0.24 + 0.66    0.05  Berberine: 52 
Coptisine:  37 
Ber + Cop 
(ratio = 5 : 1)
c 
0.47 + 0.09    0.16  Berberine:   7 
Coptisine:  15 
Curcumin  5.5  22     
ar-turmerone  9.4  150     
Cur + ar-tur 
(ratio = 1 : 6.8)
b 
0.17 + 1.2    0.09  Curcumin:  37 
ar-turmerone: 16 
Cur + ar-tur 
(ratio = 4 : 1)
d 
0.34 + 0.09    0.06  Curcumin: 18 
ar-turmerone: 87 
Berberine  7.5  30     
Curcumin  5.5  22     
Ber + Cur 
(ratio = 1.4 : 1)
b 
0.24 + 0.17    0.16  Berberine: 24 
Curcumin:  24 
         
Isolated herbal 
extracts and 
combinations 
Minimum 
Effective Dose 
(µg/ml)
a 
IC50 
(µg/ml) 
Combination 
Index (CI) 
Dose Reduction Index 
(DRI) 
Chinese Goldthread  65  130 µg/ml     
Turmeric  35  65 µg/ml     
Chinese GT + Tur 
(ratio = 2 : 1)
b 
1.10 + 0.51    0.14  Chinese GT: 52 
Turmeric:     52 
aConcentration derived from the dose-response curves where growth inhibition was significantly inhibited (p<0.05). 
bRatio based on IC50 values. 
cRatio based on relative amounts in  Chinese  goldthread. 
dRatio based on relative 
amounts in turmeric 
 
Table  4:  Dose-effect  relationships  of  berberine  and  coptisine  (from  Chinese  goldthread), 
curcumin  and  ar-turmerone  (from  turmeric),  Chinese  goldthread  and  turmeric  and  their 
combinations using their IC50 values or using ratios corresponding to relative amounts in their 
native extracts on proliferation of HEK293 cells. 
Isolated compounds and 
combinations 
Minimum 
Effective Dose 
(µM)
a 
IC50 
(µM) 
Combination 
Index (CI) 
Dose Reduction Index 
(DRI) 
Berberine  15  30     
Coptisine  18  70     
Ber + Cop 
(ratio = 1 : 2.3)
b 
3.75 + 8.75    0.42  Berberine: 5.2 
Coptisine:  4.5 
Ber + Cop 
(ratio = 5 : 1)
c 
1.88 + 0.38    0.10  Berberine:   11 
Coptisine:  109 
Curcumin  11  11     
ar-turmerone  200  400     
Cur + ar-tur 
(ratio = 1 : 36)
b 
0.69 + 25    0.45  Curcumin: 15 
ar-turmerone: 
2.6 
Cur + ar-tur 
(ratio = 4 : 1)
d 
11 + 2.75    0.64  Curcumin: 2.8 
ar-turmerone: 
1.4 
Berberine  15  30     
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Ber + Cur 
(ratio = 2.7 : 1)
b 
3.75+1.83    0.32  Berberine: 5.3 
Curcumin:  7.5 
         
Isolated herbal extracts 
and combinations 
Minimum 
Effective Dose 
(µg/ml)
a 
IC50 
(µg/ml) 
Combination 
Index (CI) 
Dose Reduction Index 
(DRI) 
Chinese Goldthread  40  80 µg/ml     
Turmeric  30  40 µg/ml     
Chinese GT + Tur 
(ratio = 2 : 1)
b 
10 + 3.75    0.29  Chinese GT: 6.8 
Turmeric:     6.8 
aConcentration derived from the dose-response curves where growth inhibition was significantly inhibited (p<0.05). 
bRatio  
based on IC50 values. 
cRatio based on relative amounts in Chinese goldthread. 
dRatio based on relative amounts in turmeric. 
 
TNFα-stimulated NF-κB transcriptional activity: Dose response curves were generated for all 
bioactives and extracts tested in HEK293 cells. All the bioactives and their extracts of origin, 
except  berberine  and  Chinese  goldthread,  reduced  NF-κB  transcriptional  activity  in  a  dose 
dependent  manner  (Fig.  4).  IC50  values  of  bioactives  were  used,  in  part,  to  determine  the 
synergistic effect between different bioactives. 
 
 
Figure 4. The effects of berberine, coptisine, curcumin, ar-turmerone, Chinese goldthread and 
turmeric on inhibition of TNFα-stimulated NF-κB transcriptional activity in HEK293 cells.  
Dose-response curves were generated with (A) berberine, coptisine, curcumin, ar-turmerone) 
and (B) Chinese goldthread and turmeric. IC50 values of the bioactives and turmeric were 
generated from these curves. 
 
Comparisons  of  turmeric  with  curcumin  on  TNFα-stimulated  NF-κB  transcriptional 
activity: Dose-response curves were generated for turmeric and curcumin and their effectiveness 
inhibiting NF-κB transcriptional activity were compared based on the relative amounts of the 
phytonutrients  in  the  herbal  extract  (i.e.,  the  amount  of  curcumin  in  turmeric).  NF-κB 
transcriptional activity was reduced in dose-dependent manners with turmeric and curcumin (Fig. 
4). Following normalization based on the relative amount of curcumin in turmeric, there was a 
shift to the left in the IC50 value, from 20 µM to 10 µM (Fig. 5). These results collectively infer 
that companion compounds in turmeric may be acting synergistically with curcumin. To explore Functional Foods in Health and Disease 2014; 4(7):312-339  Page 325 of 339 
this possibility, we investigated the effects of combining curcumin with one of its companion 
compounds ar-turmerone. 
 
 
Figure 5. The effects of curcumin and turmeric on inhibition of TNFα-stimulated 
NF-κB transcriptional activity. HEK 293 cells were treated with serial dilutions 
of  either  curcumin  or  turmeric  and  inhibition  of  TNFα-stimulated  NF-κB 
transcriptional activity  was  determined.  Following normalization based on the 
relative amount of curcumin in turmeric, dose-response curves were compared 
between curcumin in isolation to turmeric. 
 
Intra-herbal comparisons of companion phytonutrients (curcumin with ar-turmerone) on 
TNFα-stimulated NF-κB transcriptional activity: Curcumin and ar-turmerone (two bioactive 
phytonutrients found in turmeric) reduced the NF-κB transcriptional activity in dose-dependent 
manners with IC50 values of 20 µM and 275 µM, respectively (Fig. 4). To determine the effects 
on NF-κB transcriptional activity with the combination, cells were treated with curcumin plus ar-
turmerone with serial dilutions starting with concentrations equivalent to their IC50 values (20 
µM:275 µM) and reducing these to nanomolar concentrations while maintaining the same ratio 
(Table  5).  The  dose-response  curves  with  the  combination  of  curcumin  plus  ar-turmerone 
reduced  NF-κB  transcriptional  activity  in  a  dose-dependent  manner.  The  combination  of 
curcumin  plus  ar-turmerone  reduced  the  minimum  effective  concentrations  of  20  µM  for 
curcumin and 275 µM for ar-turmerone to 0.16 µM+2.15 µM for their combination, respectively 
(Table 5). The combination was highly synergistic in inhibiting NF-κB transcriptional activity 
(CI equal to 0.01 with the DRIs being 109 and 311). In a similar manner, the combination of 
curcumin plus ar-turmerone in a ratio based on relative amounts in turmeric (ratio of 4:1; Table 
5) also reduced the minimum effective doses significantly from 20 µM for curcumin and 275 µM 
for ar-turmerone to 0.63 µM+0.16 µM for their combination, respectively. This effect was also 
highly synergistic in inhibiting NF-κB transcriptional activity at these concentrations (CI equal to 
0.04 with the DRIs being 23 and 3563). 
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Inter-herbal comparison of the extracts of Chinese goldthread with turmeric on TNFα-
stimulated NF-κB transcriptional activity: The extract of Chinese goldthread did not reduce 
NF-κB  transcriptional  activity  using  concentrations  up  to  400  µg/ml  (Fig.  4B).  In  contrast, 
turmeric reduced the NF-κB transcriptional activity in a dose-dependent manner (IC50 value was 
70  µg/ml)  (Fig.  4B).  To  determine  the  effects  on  NF-κB  transcriptional  activity  with  the 
combination, cells were treated with 200 µg/ml Chinese goldthread plus progressive dilutions of 
turmeric beginning at 70 µg/ml. The combination of Chinese goldthread plus turmeric reduced 
the minimum effective dose of turmeric from 70 µg/ml to 8.75 µg/ml with the combination 
(Table 5). CI and DRI values were not generated due to the lack of a dose-response curve for 
Chinese goldthread. 
 
Table 5:  Dose-effect  relationships  of curcumin and ar-turmerone (from  turmeric), curcumin 
(from turmeric) and coptisine (from Chinese goldthread), and Chinese goldthread and turmeric 
and their combinations using their IC50 values or using ratios corresponding to relative amounts 
in their native extracts on NF-κB promoter activity using transfected HEK293 cells. 
Isolated compounds and 
combinations 
Minimum 
Effective Dose 
(µM)
a 
IC50 
(µM) 
Combination 
Index (CI) 
Dose Reduction Index (DRI) 
Curcumin 
ar-turmerone 
Cur + ar-tur 
(ratio = 1 : 14)
b 
Cur + ar-tur 
(ratio = 4 : 1)
c 
20 
275 
0.16 + 2.15 
 
0.63 + 0.16 
20 
275 
 
 
0.01 
 
0.04 
 
 
Curcumin: 109 
ar-turmerone: 311 
Curcumin: 23 
ar-turmerone: 3563 
Curcumin 
Coptisine 
Cur + Cop 
(ratio = 1 : 4)
b 
20 
80 
0.31+1.25 
20 
80 
 
 
0.03 
 
 
Curcumin: 70 
Coptisine:  42 
 
       
Isolated herbal extracts 
and combinations 
Minimum 
Effective Dose 
(µg/ml)
a 
IC50 
(µg/ml) 
Combination 
Index (CI) 
Dose Reduction Index (DRI) 
Chinese Goldthread 
Turmeric 
Chinese GT + Tur 
- 
70 
200 + 8.75 
- 
70 
 
 
- 
- 
- 
aConcentration derived from the dose-response curves where NF-κB transcription was significantly inhibited (p<0.05). 
bRatio 
based on IC50 values. 
cRatio based on relative amounts in turmeric. Abbreviations: Cur, curcumin; ar-tur, ar-turmerone; Cop, 
coptisine; Chinese GT, Chinese Goldthread; Tur, turmeric. 
 
Inter-herbal comparison of phytonutrients (coptisine with curcumin) on TNFα-stimulated 
NF-κB transcriptional activity: Berberine, just like Chinese goldthread, did not reduce NF-κB 
transcriptional activity using concentrations up to 100 µM (Fig. 4A). In an effort to explain, in 
part,  the  inter-herbal  synergism  between  Chinese  goldthread  and  turmeric,  coptisine  from 
Chinese  goldthread  and  curcumin  from  turmeric  were  evaluated  for  synergy  (Table  5).  To 
determine the effects on NF-κB transcriptional activity with the combination, cells were treated 
with curcumin plus coptisine with serial dilutions from concentrations equivalent to their IC50 
values  (20  µM:80  µM)  to  nanomolar  concentrations  while  maintaining  the  same  ratio.  The 
combination  of  curcumin  plus  coptisine  reduced  NF-κB  transcriptional  activity  in  a  dose-
dependent manner. CI and DRI values were generated for minimum effective concentrations. Functional Foods in Health and Disease 2014; 4(7):312-339  Page 327 of 339 
The  combination  of  curcumin  and  coptisine  was  highly  synergistic  in  inhibiting  NF-κB 
transcriptional activity at these levels, where the CI was equal to 0.03, and the DRIs being 70 and 
42 when combined at the minimum effective concentrations (0.31 µM+1.25 µM) (Table 5). 
 
DISCUSSION: 
It has been proposed that traditional medicines from various cultures (i.e., Traditional Chinese 
Medicine)  provide  effective  remedies  due  to  their  combinations  of  herbals,  but  there  is  a 
challenge in establishing a rationale for their superior therapeutic value compared with using 
isolated bioactives [66]. There is growing evidence that the benefits of combinations of essential 
and non-essential nutritives lie in their synergy and multiple targets of action [67]. This concept 
is presented in several reviews describing the lack of concordance between observational studies 
of bioactives compared with the foods from which the bioactives are derived (i.e., the impact of 
β-carotene versus foods that contain β-carotene on the risk of lung cancer) [3, 67].  
The mechanisms of the anticancer effects of berberine, curcumin and their herbs from which 
they are derived have been extensively studied, where they have been shown to modulate cancer 
cells to induce cell-cycle arrest, cellular apoptosis and inhibition of cell invasion and metastasis. 
Multiple signaling pathways are known to be affected (including cyclin D, caspase-3, NF-κB, 
PI3 kinase, TNF-α, COX-2, MMP-9, etc.) and are well-documented [2, 13, 21-23, 68-71]. Thus, 
it is not necessary for us to duplicate these mechanistic studies. The aim of this paper was not to 
revisit the established mechanisms of the anticancer effects of these bioactives, but to assess the 
synergistic  effect  between  bioactives  and  compare  them  to  the  herbs  from  which  they  are 
derived.  
It  has  been  suggested  that  synergy  of  polyherbals  is  related  to  their  multiple  targets  of 
action,  their  coordinated  impact  on  bioavailability,  and  their  collective  ability  to 
minimize/neutralize  adverse  side  effects  [72].  Furthermore,  while  many  bioactives  from 
botanicals have the same targets [73], it is not always clear whether the mechanisms modifying 
these targets are similar. Because of our ability to demonstrate the combinations used in this 
study function synergistically (and not additively), these data suggest while some mechanisms 
may overlap, others involve biological convergence (modifying a biological outcome, such as 
cell proliferation, via several pathways) and biochemical convergence (modifying a biochemical 
pathway, such as NF-κB transcriptional activity, via several mechanisms). 
Also important is the concept that the combination of compounds could sufficiently lower 
the effective dose/concentration when compared with the individual compounds, and similarly, 
the ability of the combination of herbs to lower the effective dose/concentration when compared 
with  individual  herbs  or  individual  bioactives  derived  from  the  herbs.  If  this  effective 
dose/concentration  can  be  sufficiently  lowered,  there  is  a  better  chance  that  it  could  have 
biological  meaning,  i.e.,  shifting  the  effective  levels  from  micromolar  to  nanomolar 
concentrations. For most underivatized bioactive phytonutrients, their effective concentrations on 
cells in culture are typically between 20-100 µM (see Table 1) [1], while the total plasma/serum 
concentrations (derivatized and underivatized) are typically two to three orders of magnitude 
lower following oral dosing (see Tables 1 and 2) [74-76].  
Investigations  in  the  chemopreventative  effects  of  phytonutrients  are  not  new,  but 
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derived, particularly through dose-reduction, may be superior because the synergy of action has 
been poorly explored. To quantitate this kind of interaction, we used the Chou-Talalay method of 
analysis [65]. This method can differentiate between synergy, additive effects and antagonism of 
combinations of agents. It is based on the use of a constant ratio of components through a variety 
of concentrations (i.e., serial dilutions) while monitoring a single end point (in our case cell 
proliferation or promoter activation). This computerized model establishes the CI (combination 
index) to determine the type of interaction, and the DRI (dose-reduction index) represents the 
magnitude of the dose reduction as a result of the combination for a given dose.  
These data are typically generated using ratios of the IC50 values from dose-response curves 
generated for each individual agent and are presented in each of the tables. Data can also be 
generated, and was  presented in  the tables,  using concentrations  that approach physiological 
relevance  where  cell  growth  was  still  significantly  inhibited.  The  DRI  is  important  at 
physiologically  relevant concentrations  (those plasma/serum  concentrations  following an oral 
dose) to establish potential therapeutic value. Because individual phytonutrients within the same 
botanical (what we refer to as “companion compounds”) exist in ratios that may be different 
from the IC50 values, we also ran a parallel set of experiments using those ratios for biological 
relevance. For example, the IC50 values for berberine and coptisine are 30 µM and 85   M, 
respectively, for a ratio of 1:2.8, but in Chinese goldthread these two compounds exist in a ratio 
closer to 5:1. The DRI can tell us to what extent one compound can enhance the effectiveness of 
another compound at a given ratio and dose compared with the compound alone [64].  
This  study  systematically  demonstrates  that  the  enhanced  effects  of  herbal  extracts 
compared with individual bioactives found in those extracts may be explained by the synergy of 
action of the companion compounds found within that extract. When the extract of turmeric was 
compared with curcumin and the extract of Chinese goldthread compared with berberine, the 
dose response curves shifted to the left suggesting companion compounds within the extracts 
could be responsible for this shift by acting in synergy. This was confirmed by establishing the 
synergy (CI values <1) between companion bioactives from the same extract (i.e., curcumin plus 
ar-turmerone from turmeric, and berberine plus coptisine from Chinese goldthread).   
In addition, this study further supports the concept that the synergy observed by combining 
two different herbal extracts could, in part, be explained by their synergistic action and due, in 
part, to the synergistic action of the combination of individual bioactives uniquely derived from 
these different sources.  This is easily illustrated by comparing our previous  results with our 
current  results  on  the  ability  of  Chinese  goldthread  and  turmeric  to  inhibit  proliferation  of 
CWR22Rv1 cells (see Supplemental Figure 1). Chinese goldthread and turmeric, when isolated 
from a polyherbal mixture, were unable to inhibit cell proliferation at doses of 4.1 μg/ml and 
11.3 μg/ml,  respectively, while our current  data demonstrates inhibition  of proliferation was 
observed at doses as low as 1.1 μg/ml and 0.5 μg/ml, respectively, when used in combination 
(Table  3).  It  is  believed  that  this  synergistic  effect  is  due,  in  part,  to  the  combinations  of 
bioactives  unique  to  each  of  the  extracts.  When  berberine  (from  Chinese  goldthread)  was 
combined with curcumin (from turmeric), the CI value demonstrated strong synergism. This 
supports the concept of improved effectiveness with targeted combinations of botanicals. 
Our  previous  studies  investigated  the  mechanisms  of  a  polyherbal  mixture  containing 
Chinese goldthread and turmeric on the inhibition of castrate-resistant PCa in vitro and in vivo Functional Foods in Health and Disease 2014; 4(7):312-339  Page 329 of 339 
[7-9].  These  inhibitory  effects  also  included  mechanisms  involving  TNFα-induced  cell 
proliferation (See Supplemental Figure 2). TNFα signals through NF-κB. As a follow-up, this 
study helps to better define the actions of two of the components in the polyherbal mixture, 
Chinese goldthread and turmeric, on this signaling pathway. Turmeric and curcumin inhibited 
NF-κB promoter activity, but Chinese goldthread and berberine were ineffective. Similar to our 
results, curcumin has been reported by others to inhibit NF-κB transcriptional activity at similar 
concentrations observed in this study (~20 µM) [77-82]. In contrast, Chinese goldthread and 
berberine did not inhibit NF-κB transcriptional activity in this study, and others report similar 
results  with  berberine  [83,  84].  Interestingly,  coptisine,  a  component  of  Chinese  goldthread, 
inhibited NF-κB transcriptional activity, but these levels were much higher (IC50 =70 µM) than 
what could be achieved as a component of Chinese Goldthread, partially explaining why Chinese 
goldthread was ineffective. Interestingly, when curcumin was used in combination with the least 
active bioactives (i.e., coptisine and ar-turmerone), curcumin enhanced their effectiveness 32 
and 3563 fold, respectively. In addition, an ineffective Chinese goldthread lowered the minimum 
effective dose of turmeric 8 fold (a CI value could not be determined due to the lack of a dose 
response with Chinese goldthread).  
Importantly, these data suggest that even when bioactives appear to have little or no activity, 
they may still act synergistically with other bioactives when used in combination, underscoring 
the concepts of biological and biochemical convergence. In addition, our data demonstrate that 
these actions of synergy may be concentration dependent. The use of concentrations higher than 
the IC50 values (i.e., IC90) for the combinations can act in a synergistic manner; however, many 
times this is not the case. In many instances, the CI values are >1 (antagonism) at concentrations 
higher  than  the  IC50  value,  but  <1  (synergy)  for  concentrations  lower  than  the  IC50,  (see 
Supplemental Table 1), underscoring the importance of concentrations used in studies. 
 
CONCLUSIONS: 
In summary, most of today’s cancers are influenced by our environment, particularly by the 
botanicals we eat (i.e., herbs, fruits, vegetables). The major source of bioactive phytonutrients is 
from  these  foods.  To  understand  the  impact  of  their  consumption,  our  objective  was  to 
investigate the concept that the combination of bioactives in botanicals is potentially far more 
effective  than  an  individual  bioactive  in  isolation.  Our  data  is  proof-of-principle  that 
combinations  of  companion  bioactives  from  the  same  source  and  bioactives  from  different 
sources act synergistically, providing some evidence that combinations found in botanicals (and 
foods)  have  advantages  over  isolated  bioactives.  Even  compounds  with  poor  efficacy  can 
become more biologically active in the presence of companion compounds. These advantages 
translate into effective doses that are more physiologic. 
 
List of abbreviations: ber, berberine; cop, coptisine; CI, combination index; cur, curcumin; 
DRI, dose reduction index; GT, goldthread; tur, turmeric;  
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   SUPPLEMENTAL FIGURES AND TABLES: 
 
 
 
 
 
 
 
Supplement Figure 1: The effects of individual herbs versus their combination on cell 
proliferation. CWR22Rv1 cells were treated with individual herbal  extracts (10.2 µg/ml 
ginger,  15.4  µg/ml  rosemary,  11.3  µg/ml  turmeric,  4.1  µg/ml  Chinese  goldthread,  10.2 
µg/ml holy basil, 8.2 µg/ml hu zhang, 4.1 µg/ml barberry, 10.2 µg/ml green tea, 2.0 µg/ml 
Baikal skullcap) or in combination equivalent to amounts used individually (76 ug/ml) for 
48 hr and cell viability was measured by MTT assay (see “Methods” section of the paper). 
For more details of the mixture see references 7-9. Treatment with individual herbal extracts 
did not significantly affect cell viability, whereas their combination significantly reduced 
cell  viability.  Data  is  presented  as  means±SD  (n=8).  Bars  with  an  asterisk  (*)  are 
significantly different from the non-treated Control at p<0.05. Functional Foods in Health and Disease 2014; 4(7):312-339  Page 337 of 339 
 
Supplemental Figure 2. CWR22Rv1 cell were treated with a combination of herbal extracts 
(composition: 10.2 µg/ml ginger, 15.4 µg/ml rosemary, 11.3 µg/ml turmeric, 4.1 µg/ml Chinese 
goldthread, 10.2 µg/ml holy basil, 8.2 µg/ml hu zhang, 4.1 µg/ml barberry, 10.2 µg/ml green tea, 
2.0 µg/ml baikal skullcap) with increasing combined concentrations (0, 15, 30, 38, 57, 76 ug/ml) 
with or without TNF-α (10 ng/ml) for 0, 24, 48, 72, and 96 hr. For more details of the herbal 
mixture see references 7-9. Cell viability was measured by MTT assay (see “Methods” section of 
the paper). TNF-α had a progressive effect on cell proliferation over time and this effect was 
attenuated in the presence of herbal mixture in a dose-dependent manner. Data is presented as 
means±SD (n=8). 
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Supplemental Table 1: Dose-effect relationships of Chinese goldthread, turmeric, berberine, 
coptisine, curcumin and ar-turmerone and their combinations on proliferation of CWR22Rv1 
and HEK293 cells and NF-κB promoter activity. 
Compounds / 
combinations 
Dm 
(µM) 
m  r  CI 
IC25 
CI 
IC50 
CI 
IC75 
CI 
IC90 
DRI- 
IC25 
DRI- 
IC50 
DRI- 
IC75 
DRI- 
IC90 
DRI- 
IC25 
DRI- 
IC50 
DRI- 
IC75 
DRI- 
IC90 
Inhibition of Proliferation using CWR22Rv1 Cells    Ber  Ber  Ber  Ber  Cop  Cop  Cop  Cop 
Berberine  23.1  1.7  0.9                         
Coptisine  96.7  0.8  0.9                         
Ber:Cop (1: 2.8)
a  27.2  0.6  0.8  0.2  0.5  1.5  4.7  11.8  3.3  0.9  0.1  8.4  4.8  2.7  1.6 
Ber:Cop (5: 1)
b  25.3  1.2  0.9  0.8  0.9  1.2  1.6  1.4  1.1  0.8  0.6  14.5  22.9  36.3  57.3 
Inhibition of Proliferation using CWR22Rv1 Cells    Cur  Cur  Cur  Cur  ar-T  ar-T  ar-T  ar-T 
Curcumin  11.4  2.1  0.9                         
ar-turmerone  328.3  0.4  0.9                         
Cur:ar-T (1:6.8)
a  13.8  1.2  0.7  0.3  0.2  0.2  0.4  10.0  6.4  4.1  2.7  6.0  27.3  124  564 
Cur:ar-T (4: 1)
b  4.4  1.0  0.8  0.2  0.3  0.6  1.1  6.1  3.2  1.7  0.9  99.4  371  1386  5173 
Inhibition of Proliferation using CWR22Rv1 Cells    Ber  Ber  Ber  Ber  Cur  Cur  Cur  Cur 
Berberine  23.1  1.7  0.9                         
Curcumin  11.4  2.1  0.9                         
Ber:Cur (1.4: 1)
a  13.8  1.2  0.7  0.5  0.6  0.7  0.9  4.8  4.3  3.9  3.5  3.9  2.9  2.1  1.6 
Inhibition of Proliferation using CWR22Rv1 Cells    CG  CG  CG  CG  Tur  Tur  Tur  Tur 
Chinese 
goldthread 
106  1.6  0.9                         
Turmeric  49.6  1.8  0.8                         
Chinese GT: 
Tur (2: 1)
a 
87.5  0.6  0.8  0.3  1.1  3.7  12  5.7  1.8  0.6  0.2  5.8  1.7  0.5  0.2 
Inhibition of Proliferation using HEK293 Cells    Ber  Ber  Ber  Ber  Cop  Cop  Cop  Cop 
Berberine    42.9  2.6  0.9                         
Coptisine  81.9  2.8  0.9                         
Ber:Cop (1:2.3)
a  51.2  2.0  0.9  0.7  0.8  0.9  1.0  3.2  2.8  2.5  2.2  2.7  2.3  2.0  1.7 
Ber:Cop (5: 1)
b  33.3  1.0  0.9  0.3  0.7  1.5  3.0  3.2  1.5  0.8  0.4  31.3  14.8  7.0  3.3 
Inhibition of Proliferation using HEK2931 Cells    Cur  Cur  Cur  Cur  ar-T  ar-T  ar-T  ar-T 
Curcumin  17.3  3.2  0.9                         
ar-turmerone  400.6  1.0  0.9                         
Cur:ar-T (1:6.8)
a 100.3  1.3  0.9  0.4  0.4  0.4  0.6  10.6  6.4  4.0  2.4  3.1  4.1  5.5  2.4 
Cur:ar-T (4: 1)
b  11.1  1.5  0.8  0.4  0.5  0.8  1.1  2.9  1.9  1.3  0.9  122  180  267  395 
Inhibition of Proliferation using HEK2931 Cells    Ber  Ber  Ber  Ber  Cur  Cur  Cur  Cur 
Berberine  37.8  2.6  0.9                         
Curcumin  17.2  3.2  0.9                         
 Ber:Cur (1.4: 1)
a  18.0  1.9  0.9  0.5  0.6  0.8  0.9  3.3  2.9  2.5  2.1  4.5  3.6  2.8  2.2 
Inhibition of Proliferation using HEK2931 Cells    Ber  Ber  Ber  Ber  Cur  Cur  Cur  Cur 
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goldthread 
Turmeric  49.3  2.9  0.8                         
Chinese GT: 
Tur (2: 1)
a 
73.7  2.6  0.9  0.8  0.8  0.8  0.8  2.7  2.8  3.0  3.1  2.6  2.5  2.4  2.3 
NF-κB Promoter Activity using Transfected HEK293 
Cells 
  CG  CG  CG  CG  Tur  Tur  Tur  Tur 
Curcumin  35.0  1.3  0.5                         
ar-turmerone  1418  1.3  0.5                         
Cur:ar-T (1: 14)
a  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
Cur:ar-T (4: 1)
b  43  0.8  0.4  0.6  0.9  1.7  2.9  1.8  1.0  0.6  0.3  273  166  101  61 
NF-κB Promoter Activity using Transfected HEK293 
Cells 
  Cur  Cur  Cur  Cur  Cop  Cop  Cop  Cop 
Curcumin  35.0  1.3  0.5                         
Coptisine  90.3  1.1  0.6                         
Cur: Cop (1:4)
a     16.2  0.7  0.8  0.1  0.2  0.4  0.7  20.5  10.8  5.7  3.0  11.6  7.0  4.2  2.5 
 
Dm: median-effect dose (concentration which inhibits cell growth by 50%). m: shape of the dose-
effect curves, where m=1, hyperbolic; m>1, sigmoidal; and m<1, flat sigmoidal, respectively. r: 
linear  correlation  coefficient  of  the  median-effect  plot  (indicates  conformity  of  data). 
aRatio 
based on IC50 values. 
bRatio based on relative amounts in Chinese goldthread.  
 
Abbreviations: ar-T, ar-turmerone; Ber, berberine; CG, Chinese goldthread; CI, combination 
index; Cop, coptisine; Cur: curcumin; DRI, dose reduction index. 
 
 
 